In the wake of the COVID-19 health crisis, the entire biopharmaceutical industry is coming together to ensure the advancement of patient access to critical research studies and novel treatments. Together, we are working to remove barriers to make trial and research access safe and convenient, by accelerating the adoption of technology-enabled remote data collection practices.<\/p>\n\n\n\n
\u201cWe are honored to join the DTRA at such a pivotal moment for the entire healthcare system. The pandemic has presented myriad challenges for pharmaceutical manufacturers, research organizations, and regulators\u201d said Aaron Berger, Executive Director, Late Stage Operations & RWE, a leading voice in evidence generation strategies. \u201cTo meet these challenges, a robust array of decentralized trial solutions are needed, including digital patient engagement, technology-enabled data acquisition, and in-home nursing. We are introducing one or more of these strategies into study design discussions with our sponsor partners.\u201d<\/p>\n\n\n\n
Since March, UBC\u2019s comprehensive suite of solutions has helped many clients mitigate the risks that surround bringing treatments to market in today\u2019s challenging environment.<\/p>\n\n\n\n
\u201cThrough the utilization of direct-to-patient and digital strategies, we have been able to modernize and accelerate the way we gather critical data and insights needed for regulatory decisions and beyond. Our wide array of decentralized study capabilities to collect critical evidence beyond the walls of the traditional study setting, remotely or in the patient\u2019s home. These are the types of experiences we are keen to share with fellow leaders and industry stakeholders as part of our role in the DTRA and the future of clinical development.\u201d Berger concludes.<\/p>\n\n\n\n